CNTN vs CNTX

Canton Strategic Holdings, Inc. vs Context Therapeutics Inc. — Valuation Comparison 2026

CNTN

Biotechnology
Canton Strategic Holdings, Inc.
Quality
3.5
out of 10
Value Trap
24
SAFE
Price
$3.11
Last close
Models
7/13
Active
VS

CNTX

Biotechnology
Context Therapeutics Inc.
Quality
4.5
out of 10
Value Trap
18
SAFE
Price
$2.83
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CNTN Fair ValueCNTN Upside CNTX Fair ValueCNTX Upside
Bayesian DCF Intrinsic $1.15 -62.9% $1.08 -61.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $3.17 +2.0% $0.10 -95.5%
Dynamic NAV Asset-Based $2.82 -9.3% $0.89 -68.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CNTN vs CNTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CNTN vs CNTX — Which Stock Is More Undervalued?

CNTX scores higher with a 4.5/10 quality rating vs CNTN's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Canton Strategic Holdings, Inc. (CNTN) and Context Therapeutics Inc. (CNTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CNTN currently trades at $3.11 with a QOC of 3.5/10, while CNTX trades at $2.83 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).